Lyrica Scheduling Decision Expected In Second Quarter; Launch To Follow
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer hopes to complete the DEA scheduling process for Lyrica during the second quarter, clearing the way for the launch of the neuropathic pain agent
You may also be interested in...
NeurogesX Reports Successful Phase III Trial For NGX-4010 In Post-Herpetic Neuralgia
Firm plans to file with EMEA for peripheral neuropathic pain indication later this year.
NeurogesX Reports Successful Phase III Trial For NGX-4010 In Post-Herpetic Neuralgia
Firm plans to file with EMEA for peripheral neuropathic pain indication later this year.
Pfizer’s Lyrica: DEA Proposes Schedule V Designation, Comments Due June 13
The pregabalin launch is at least a month away following the Drug Enforcement Administration’s proposed rule on controlled substance scheduling for the neuropathic pain agent. Lyrica has a “low potential for abuse” relative to Schedule IV substances, DEA says.